|
PANAMA CITY, Feb. 3, 2026 /PRNewswire/ -- BingX, a leading cryptocurrency exchange and Web3-AI company, today announced a significant milestone for its TradFi perpetual futures offering, as 24-hour trading volume doubled over the past week to exceed $2 billion. The surge was largely driven by strong demand for perpetual Gold trading, which alone contributed more than $1.5 billion in volume, underscoring growing user interest in round-the-clock access to traditional financial markets through crypto-native infrastructure.
BingX TradFi is now fully integrated across the BingX ecosystem:
- Perpetual Futures: BingX provides comprehensive support for TradFi perpetual futures, enabling users to gain continuous, flexible exposure to commodities, forex, stocks, and indices through crypto-native infrastructure, competitive fees, and leverage of up to 500x.
- Copy Trading: As the original pioneer of copy trading in Web3, BingX offers industry-leading TradFi copy trading, reducing barriers to entry by enabling users to follow experienced traders and replicate TradFi trading strategies.
- Spot Markets: On the spot market, BingX supports assets such as Ondo and xStocks, allowing users to purchase real-world asset (RWA) tokens backed by underlying traditional financial instruments.
- BingX AI: BingX TradFi is integrated with BingX AI Bingo to support smarter trade discovery, execution, and overall usability, contributing to a more seamless TradFi trading experience across the platform.
"Five years ago, discussions centered on whether crypto could rival gold or equities as a store of value," said Vivien Lin, Chief Product Officer of BingX. "Today, users can trade gold and equities directly using crypto. These two parallel shifts: the maturation of crypto markets and the tokenization and perpetualization of traditional assets, are converging and fundamentally reshaping how global finance operates."
To further engage users, BingX has launched a TradFi perpetual futures trading volume competition, featuring a dynamic prize pool of up to 200,000 USDT. The prize pool increases as total trading volume across all participants grows, rewarding collective participation and encouraging active engagement with TradFi perpetual futures on the platform.
About BingX
Founded in 2018, BingX is a leading crypto exchange and Web3-AI company, serving over 40 million users worldwide. Ranked among the top five global crypto derivatives exchanges and a pioneer of crypto copy trading, BingX addresses the evolving needs of users across all experience levels.
Powered by a comprehensive suite of AI-driven products and services, including futures, spot, copy trading, and TradFi offerings, BingX empowers users with innovative tools designed to enhance performance, confidence, and efficiency.
BingX has been the principal partner of Chelsea FC since 2024, and became the first official crypto exchange partner of Scuderia Ferrari HP in 2026.
For more information, please visit: https://bingx.com/
PANAMA CITY, Feb. 3, 2026 /PRNewswire/ -- BingX, a leading cryptocurrency exchange and Web3-AI company, today announced a significant milestone for its TradFi perpetual futures offering, as 24-hour trading volume doubled over the past week to exceed $2 billion. The surge was largely driven by strong demand for perpetual Gold trading, which alone contributed more than $1.5 billion in volume, underscoring growing user interest in round-the-clock access to traditional financial markets through crypto-native infrastructure.
BingX TradFi is now fully integrated across the BingX ecosystem:
- Perpetual Futures: BingX provides comprehensive support for TradFi perpetual futures, enabling users to gain continuous, flexible exposure to commodities, forex, stocks, and indices through crypto-native infrastructure, competitive fees, and leverage of up to 500x.
- Copy Trading: As the original pioneer of copy trading in Web3, BingX offers industry-leading TradFi copy trading, reducing barriers to entry by enabling users to follow experienced traders and replicate TradFi trading strategies.
- Spot Markets: On the spot market, BingX supports assets such as Ondo and xStocks, allowing users to purchase real-world asset (RWA) tokens backed by underlying traditional financial instruments.
- BingX AI: BingX TradFi is integrated with BingX AI Bingo to support smarter trade discovery, execution, and overall usability, contributing to a more seamless TradFi trading experience across the platform.
"Five years ago, discussions centered on whether crypto could rival gold or equities as a store of value," said Vivien Lin, Chief Product Officer of BingX. "Today, users can trade gold and equities directly using crypto. These two parallel shifts: the maturation of crypto markets and the tokenization and perpetualization of traditional assets, are converging and fundamentally reshaping how global finance operates."
To further engage users, BingX has launched a TradFi perpetual futures trading volume competition, featuring a dynamic prize pool of up to 200,000 USDT. The prize pool increases as total trading volume across all participants grows, rewarding collective participation and encouraging active engagement with TradFi perpetual futures on the platform.
About BingX
Founded in 2018, BingX is a leading crypto exchange and Web3-AI company, serving over 40 million users worldwide. Ranked among the top five global crypto derivatives exchanges and a pioneer of crypto copy trading, BingX addresses the evolving needs of users across all experience levels.
Powered by a comprehensive suite of AI-driven products and services, including futures, spot, copy trading, and TradFi offerings, BingX empowers users with innovative tools designed to enhance performance, confidence, and efficiency.
BingX has been the principal partner of Chelsea FC since 2024, and became the first official crypto exchange partner of Scuderia Ferrari HP in 2026.
For more information, please visit: https://bingx.com/
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
BingX TradFi Daily Trading Volume Doubles in One Week, Surpassing $2 Billion and Defying the Trend
HANGZHOU, China, April 3, 2026 /PRNewswire/ -- A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A high-throughput selection system for fast-acting covalent protein drugs," opens new avenues for next-generation biologics.
Covalent small-molecule drugs have shown great success in cancer therapy by forming irreversible bonds with their targets. This has inspired efforts to extend covalent strategies to protein therapeutics, especially engineered miniproteins. However, their development is limited by a kinetic mismatch: Miniproteins are rapidly cleared in vivo, whereas covalent bond formation is typically slow. In addition, high-throughput platforms for systematically optimizing covalent protein reactivity have been lacking.
To address this challenge, the researchers proposed that precise spatial positioning of chemical warheads within protein scaffolds could enable molecular preorganization, thereby accelerating covalent bond formation without increasing intrinsic reactivity (Fig. 1).
Based on this concept, the team developed a high-throughput platform that combines yeast surface display with chemoselective protein modification to screen diverse crosslinkers and millions of protein variants. By optimizing warhead placement and the local chemical environment, the platform enables rapid and irreversible target engagement.
Using this platform, the researchers developed a covalent antagonist targeting PD-L1, termed IB101. Structural analysis revealed that IB101 forms a defined binding pocket that precisely positions the warhead in a reactive conformation, greatly accelerating covalent bond formation. Functionally, IB101 effectively blocks the PD-1/PD-L1 immune checkpoint pathway and demonstrates strong antitumor activity in mouse models. Notably, despite its short in vivo half-life, IB101 achieves durable target engagement and tumor suppression, outperforming conventional antibody-based therapies under comparable conditions.
The platform was further applied to cytokine engineering, leading to the development of a covalent IL-18 variant, IB201. This engineered cytokine rapidly forms a covalent interaction with its receptor, enhancing signaling strength and duration. In vivo studies showed that IB201 induces potent antitumor immune responses without detectable systemic toxicity. These results highlight the potential of covalent engineering to improve the efficacy and safety of cytokine-based therapies.
Beyond immunotherapy targets, the platform was also applied to develop a covalent inhibitor targeting the receptor-binding domain (RBD) of SARS-CoV-2. This molecule achieves durable viral neutralization, demonstrating the versatility of the approach across different therapeutic modalities.
This study establishes a general strategy for engineering fast-acting covalent protein therapeutics. By enabling covalent bond formation on timescales compatible with rapid in vivo clearance, the platform overcomes a fundamental limitation in the field.
These findings provide a new framework for designing biologics with both rapid kinetics and sustained target engagement, with broad implications for cancer immunotherapy, antiviral therapy, and beyond.
Media Contact:
Chi Zhang
media@westlake.edu.cn
+86-15659837873
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Fast-Acting Covalent Protein Drugs From a New High-Throughput Platform
